A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. This story was originally published on BioPharma Dive. To ...

Eli Lilly and Company’s LLY announced that a late-stage study evaluating its already approved cancer drug, Cyramza for the second-line treatment of liver cancer met the primary as well as secondary ...

Lilly's CYRAMZA (ramucirumab) significantly improved overall survival in phase 3 non-small cell lung cancer study. Results from the REVEL trial were published in The Lancet and also presented at ASCO ...

Eli Lilly’s chances of snagging an abemaciclib approval as wide as those of its rivals are looking even better, thanks to new survival data announced on Monday. But analysts are still questioning ...

Oct 13 (Reuters) - Johnson & Johnson said the proven ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be seen in the ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...